The changing treatment landscape in idiopathic pulmonary fibrosis

被引：20

作者：

Costabel, Ulrich ^{[1
]}

机构：

[1] Univ Duisburg Essen, Univ Hosp, Interstitial & Rare Lung Dis Unit, Ruhrlandklin, Essen, Germany

来源：

EUROPEAN RESPIRATORY REVIEW | 2015年 / 24卷 / 135期

关键词：

D O I：

10.1183/09059180.00011414

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2-5 years following diagnosis) is poorer than that of some cancers and for many years no significant advances were made in its management. However, between 2011 and 2014 a number of pivotal developments were made that have improved the outlook for patients with IPF. Herein, we review this rapidly changing landscape, discussing key events whilst still acknowledging that IPF remains a challenging disease to diagnose and manage.

引用

页码：65 / 68

页数：4

共 34 条

[1]

Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646

[2] Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis [J].

Arai, Toru ;

Inoue, Yoshikazu ;

Sasaki, Yumiko ;

Tachibana, Kazunobu ;

Nakao, Keiko ;

Sugimoto, Chikatoshi ;

Okuma, Tomohisa ;

Akira, Masanori ;

Kitaichi, Masanori ;

Hayashi, Seiji .

RESPIRATORY INVESTIGATION, 2014, 52 (02) :136-143

[3] Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis [J].

Bonella, F. ;

Wessendorf, T. E. ;

Costabel, U. .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (11) :518-523

[4] Real world experiences: Pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis [J].

Chaudhuri, Nazia ;

Duck, Annette ;

Frank, Rebecca ;

Holme, Jayne ;

Leonard, Colm .

RESPIRATORY MEDICINE, 2014, 108 (01) :224-226

[5] Acute exacerbations of idiopathic pulmonary fibrosis [J].

Collard, Harold R. ;

Moore, Bethany B. ;

Flaherty, Kevin R. ;

Brown, Kevin K. ;

Kaner, Robert J. ;

King, Talmadge E., Jr. ;

Lasky, Joseph A. ;

Loyd, James E. ;

Noth, Imre ;

Olman, Mitchell A. ;

Raghu, Ganesh ;

Roman, Jesse ;

Ryu, Jay H. ;

Zisman, David A. ;

Hunninghake, Gary W. ;

Colby, Thomas V. ;

Egan, Jim J. ;

Hansell, David M. ;

Johkoh, Takeshi ;

Kaminski, Naftali ;

Kim, Dong Soon ;

Kondoh, Yasuhiro ;

Lynch, David A. ;

Mueller-Quernheim, Joachim ;

Myers, Jeffrey L. ;

Nicholson, Andrew G. ;

Selman, Moises ;

Toews, Galen B. ;

Wells, Athol U. ;

Martinez, Fernando J. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (07) :636-643

[6] Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis [J].

Cordier, Jean-Francois ;

Cottin, Vincent .

EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (04) :916-923

[7]

Costabel U, 2014, SARCOIDOSIS VASC DIF, V31, P198

[8] Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events [J].

Costabel, Ulrich ;

Bendstrup, Elisabeth ;

Cottin, Vincent ;

Dewint, Pieter ;

Egan, Jim J. J. ;

Ferguson, James ;

Groves, Richard ;

Hellstrom, Per M. ;

Kreuter, Michael ;

Maher, Toby M. ;

Molina-Molina, Maria ;

Nordlind, Klas ;

Sarafidis, Alexandre ;

Vancheri, Carlo .

ADVANCES IN THERAPY, 2014, 31 (04) :375-391

[9]

European Medicines Agency, EMACHMP1151472011

[10] Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK [J].

Gribbin, J. ;

Hubbard, R. B. ;

Le Jeune, I. ;

Smith, C. J. P. ;

West, J. ;

Tata, L. J. .

THORAX, 2006, 61 (11) :980-985

← 1 2 3 4 →